Bcl-2 expression as a prognostic factor of survival of gastric carcinoma

Anticancer Research

Volumn 18, Issue 3 B, 1998, Pages 2003-2010

  Inada, Takao ^a   Kikuyama, Shigehiro ^b   Ichikawa, Akira ^a   Igarashi, Seiji ^a   Ogata, Yoshiro ^a  

^a TOCHIGI CANCER CENTER   (Japan)

^b National Hospital Organization Tochigi Medical Center   (Japan)

Author keywords

Apoptosis; Bcl 2 protein; Gastric cancer; p53 protein

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; STOMACH CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031903711     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Stewart BW: Mechanism of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86: 1286-1296, 1994.
2. Liu T, El-Naggar AK, McDonnell TJ: Steck KD, Wang M, Taylor DL and Clayman GI: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of head and neck. Cancer Res 55: 3117-3122, 1995.
3. Korsmeyer S: bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
4. Lotem J and Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4: 41-71, 993.
5. Miyashita T and Reed JC: bcl-2 gene transfer increases relative resistance of S 49.1 and WEHI 7.2 lymphoid cells to cell death-DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411, 1992.
6. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
7. Hockenbery D, Zutter M, Hickey W, Nahm M and Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.
8. Umeyama S, Kawai K, Osamura RY and Tsusumi Y: Antigen retrieval for bcl-2 protein in formalin-fixed, paraffin-embedded sections. Pathol Int 45: 103-107, 1995.
9. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM and Frizzera G: bcl-2 and other Genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320: 690-694, 1993.
10. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DM: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694, 1993.
11. Takayama K, Ogata K, Nakanishi Y, Yatsunami J, Kawasaki M and Hara N: Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer J Sci Am 2: 212-6, 1996.
12. Sinicrope FA, Hart J, Michelassi FM and Lee JJ: Prognostic value of bcl-2 oncoprotein expression in Stage II colon carcinoma. Clin Cancer Res 1: 1103-10, 1995.
13. Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsh M, Bocker W, Jasani B and Schmid KW: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer 72: 981-985, 1995.
14. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di-Fronzo G, Rilke F and Veronesi N: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
15. Joensuu H, Pylkkanen L and Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198, 1994.
16. Gasparini G, Barbarenschi M, Doglioni C, Dalla Palma P, Angelo Mauri FA, Borrachi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F and Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1: 189-198, 1995.
17. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ: The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184, 1996.
18. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
19. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L7 Kimichi A and Oren M: Wild-type p53 induces Apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond) 352: 345-347, 1991.
20. Greenblatt MS, Bennett WP, Hollenstein M and Harr CC: Mutations in the p53 tumor suppressor gene cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-78, 1994.
21. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R and Takahashi T: Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancer. J Clin Oncol 14: 497-502, 1996.
22. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69: 135-139, 1994.
23. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
24. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma. 1st English ed. Tokyo, Kanehara Shuppan, 1995.
25. Hedley DW, Friedlander ML and Taylor IW: Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 6: 327-333, 1985.
26. Gavrieli Y, Sherman Y and Ben-Sasson SS: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1991.
27. Inada T, Ichikawa A, Kubota T, Ogata Y, Moossa A and Huffman RM: 5-FU-induced apoptosis correlates with efficacy Against human gastric and colon cancer xenografts in nude mice. Anticancer Res 17: 1965-1972, 1997.
28. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1985.
29. Cox DR: Regression models and life tables. J R Stat Soc Series B 34: 187-220, 1972.
30. Ohyama S, Yonemura Y and Miyazaki I: Proliferate activity and malignancy in human gastric cancers. Significance of the proliferation rate and its clinical application. Cancer 69: 314-21, 1991.
31. Inada T, Imura J, Ichikawa A, Ogata Y and Shimamura K: Proliferative activity of gastric cancer assessed by immunostaining for proliferating cell nuclear antigen. J Surg Oncol 54: 146-152, 1993.
32. Kasagi N, Gomyo Y, Shirai H, Tsujitani S and Ito H: Apoptotic cell death in human gastric carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling, Jpn J Cancer Res 85: 939-945, 1994.
33. Uesugi H, Saegusa M, Takano Y and Okayasu I: Different expression of Bcl-2 protein in gastric adenomas and carcinomas. Pathol Int 46: 274-280, 1996.
34. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K. Schneiderbanger K, Schmidt M and Lohrs U: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: aspects of carcinogenesis and prognostic significance. Cancer (Phila) 77: 255-264, 1996.
35. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler K and Vogelstein B: Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 54: 3714-3717, 1994.
36. Allsopp TE, Wyatt S, Paterson HF and Davies AM: The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73: 295-307, 1993.
37. Korsmeyer SJ: Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 88: 386-401, 1996.
38. Oltvai Z, Milliman C and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.